Dipòsit Digital de Documents de la UAB 2 registres trobats  La cerca s'ha fet en 0.00 segons. 
1.
12 p, 1.8 MB Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study / Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ; Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ; Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ; Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ; Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ; McCarthy, Helen (Royal Bournemouth General Hospital) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ; Kipps, Thomas J. (UCSD Moores Cancer Center) ; Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798  
2.
11 p, 1.8 MB Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma / Munir, T. (Department of Haematology. St. James's University Hospital) ; Brown, J.R. (CLL Center. Dana-Farber Cancer Institute) ; O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ; Barrientos, J.C. (Division of Medical Oncology and Hematology Northwell Health Cancer Institute) ; Barr, P.M. (Wilmot Cancer Institute. University of Rochester Medical Center) ; Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ; Coutre, S. (Stanford Cancer Center. Stanford University School of Medicine) ; Tam, C.S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ; Mulligan, S.P. (Royal North Shore Hospital) ; Jaeger, U. (Division of Hematology and Hemostaseology. Medical University of Vienna) ; Kipps, T.J. (UCSD Moores Cancer Center) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Montillo, M. (Niguarda Ca' Granda Hospital) ; Burger, J.A. (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Byrd, J.C. (The Ohio State University Comprehensive Cancer Center) ; Hillmen, P. (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Dai, S. (Pharmacyclics LLC. an AbbVie Company) ; Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ; Dean, J.P. (Pharmacyclics LLC. an AbbVie Company) ; Woyach, J.A. (The Ohio State University Comprehensive Cancer Center) ; Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363  

Vegeu també: autors amb noms similars
1 Coutre, S.E.
1 Coutre, Steven
1 Coutre, Steven E.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.